Special Issue "Ion Channels as a Therapeutic Target: Drug Design and Pharmacological Investigation 2.0. [PDF]
Guerrini G, Giovannoni MP.
europepmc +1 more source
Do all voltage-gated potassium channels use MiRPs? [PDF]
Abbott, GW, Goldstein, SA, Sesti, F
core
Assembly of Voltage-gated Potassium Channels [PDF]
Jia Xu +4 more
openaire +1 more source
Genetic epilepsies with myoclonic seizures: Mechanisms and syndromes
Abstract Genetic epilepsy with myoclonic seizures encompasses a heterogeneous spectrum of conditions, ranging from benign and self‐limiting forms to severe, progressive disorders. While their causes are diverse, a significant proportion stems from genetic abnormalities.
Antonietta Coppola +3 more
wiley +1 more source
Beyond sodium channel blockade: Flavonoid as alternative local anesthetic candidates of lidocaine. [PDF]
Takeda M, Utugi S, Toyota R, Sashide Y.
europepmc +1 more source
Precision therapies for genetic epilepsies in 2025: Promises and pitfalls
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang +3 more
wiley +1 more source
The molecular basis of KCNH1-related epileptic encephalopathy and the challenge of developing targeted therapeutics. [PDF]
Sundman AK, Jin S, Vadlamudi L, King GF.
europepmc +1 more source
Status epilepticus: Updates on mechanisms and treatments
Abstract Status epilepticus (SE) consists of prolonged, self‐sustaining seizures and is a common neurological emergency that causes respiratory compromise and neuronal injury. Without prompt treatment, the seizures can become resistant to benzodiazepines, leading to the progressive evolution of established, refractory, and super‐refractory SE.
Suchitra Joshi, Jaideep Kapur
wiley +1 more source
The Helix Ring Peptide U11 from the Venom of the Ant, Tetramorium bicarinatum, Acts as a Putative Pore-Forming Toxin, Not a New Kv1.3 Channel Blocker. Comment on Boy et al. A New Kv1.3 Channel Blocker from the Venom of the Ant Tetramorium bicarinatum. Toxins 2025, 17, 379. [PDF]
Peigneur S, Tibery D, Tytgat J.
europepmc +1 more source

